LipoNova AG
LipoNova AG: LipoNova AG recruits renowned international experts for Business Advisory Board
LipoNova AG / Change of Personnel Release of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer / publisher is solely responsible for the content of this announcement. ---------------------------------------------------------------------- Hanover, May 3rd 2007. - LipoNova AG (WKN LNAG00), a Phase III biotech company, has succeeded in recruiting renowned biotech and capital market experts from Europe and the USA for its Business Advisory Board. This Board was formed on April 15, 2007 and will support LipoNova on all scientific matters as well as in the areas of fundraising and the capital market. It comprises the following individuals: (1) Matthew N. Murray, investment banker and biotech analyst. Matthew has years of experience in the biotech sector as well as an outstanding network in the USA and was the founder of New York Private Equity. He has previously worked for companies such as Rodman & Renshaw, Lehman Brothers and UBS. (2) Ernesto A. M. Mancosu, Director of Corporate Finance at Kepler Equities. Ernesto previously worked for Lombard Odier Darier Hentsch and will support LipoNova as an expert on Corporate Finance, Life Science and Mergers & Acquisitions. (3) Daniel Jan Ellens, venture partner at Life Sciences Partners and previously the Chief Operating Officer of Berna Biotech and Chief Executive Officer of Rhein Biotech Daniel brings years of experience as an entrepreneur with international life sciences companies, especially in the area of vaccines. (4) Professor Raymond L. Powles CBE, Director of the Leukaemia & Myeloma department of the Parkside Cancer Center, Parkside Hospital in London. He also holds the postions of Emeritus Professor of Haematological Oncology at the Institute of Cancer Research, London and Chairman of the American Society of Haematology Committee. Ray will be supporting LipoNova as an expert in the assessment of technical development possibilities for commercially viable products with clinical need. 'We are delighted to have gained these four internationally recognized experts for our newly created Business Advisory Board,' stated Dr. Claudia Ulrich, CEO of LipoNova. 'This confirms our therapy approach and the enormous worldwide potential for tumor vaccines in the treatment of cancer. These specialists will help us to prepare for the international commecialisation of our lead product candidate 'Reniale' which is being developed for the treatment of kidney cell carcinoma'. About LipoNova AG: LipoNova is an international pioneer in the development of a completely new set of substances for cancer therapy, so-called 'autologous tumor vaccines'. LipoNova is the first company in the world to successfully conclude a Phase III clinical study in this area with the product candidate 'Reniale'. LipoNova intends to develop the product candidate for the treatment of kidney cell carcinomas until it is ready for international marketing – the market potential is estimated at approximately 1 billion Euro per annum. Moreover, it forms the basis for the development of other products for prolonging life using this technology. Contact: edicto GmbH Axel Mühlhaus/ Werner Rüppel Tel. 069-9055055-2 E-mail: amuehlhaus@edicto.de DGAP 03.05.2007 ---------------------------------------------------------------------- Language: English Issuer: LipoNova AG Feodor-Lynen-Str. 35 30625 Hannover Deutschland Phone: +49 (0)511-54099 0 Fax: +49 (0)511-54099 31 E-mail: info@liponova.de www: www.liponova.de ISIN: DE000LNAG002 WKN: LNAG00 Indices: Listed: Freiverkehr in Berlin-Bremen, Düsseldorf, Stuttgart; Entry Standard in Frankfurt End of News DGAP News-Service ---------------------------------------------------------------------------
Aktuelle News
Aktuelle Berichte
Keine Berichte gefunden
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden